谢谢哦,好人一生平安。作者: lr8225009 时间: 2013-8-29 10:30
应该是叫肌萎縮性脊髓側索硬化症(ALS, Amyotrophic lateral sclerosis),又稱路格瑞氏症(Lou Gehrig's disease),肌萎缩侧索硬化症,俗稱為漸凍人症。
我关心这个病也很久了。 实话实说,如果确诊的话,基本上是没有什么办法的。
全世界只有美国有正规的临床试验,但是才只有第P1/P2,我把网站发给你http://www.neuralstem.com/ ,你可以试试去APPLY。看了下现在是P2,在墨西哥城招人。这是唯一一个FDA APPROVED的试验。
Neuralstem ALS Trial
Neuralstem received FDA approval to commence the NSI-566/ALS Phase II trial in April 2013, following conclusion of its Phase I FDA-approved trial to test the safety of its cells and transplantation surgery in patients with ALS in February 2013. The National Institutes of Health and ALSA have committed to generous grants in funding for this phase of the study.
The NSI-566/ALS Phase II dose escalation and safety trial will expand to two centers: Emory University Hospital in Atlanta, Georgia, site of Phase I, and ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, subject to approval by the Institutional Review Board at each institution. The trial is designed to treat up to 15 patients, in five different dosing cohorts, advancing up to a maximum of 40 injections, and 400,000 cells per injection based on safety. (Phase I maximum was 15 injections of 100,000 cells each.) All of the patients will be ambulatory and reside within close geographic proximity to the research center where they will participate. The first 12 patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function. The final three patients will receive both cervical and lumbar injections.
The Phase I safety trial enrolled 18 patients. The trial began with 12 late- to mid-stage patients who received a series of injections in the L2-L4 lumbar region. The first six patients were all non-ambulatory with permanent paralysis. Of these, the first three patients (Cohort A1) were treated with five unilateral cell injections, while the next three patients (Cohort A2) received ten bilateral injections in the same region. The trial then progressed to patients who were ambulatory. The first three of these (Cohort B) received five unilateral injections. The next three patients (Cohort C) received ten bilateral injections in the same lumbar region.
Neuralstem received approval from the FDA to move into the cervical (upper back) stage of the trial in the fall of 2011. The first of six patients in the cervical cohorts to receive stem cells was treated on November 18, 2011, which marked the first FDA-approved intraspinal surgical transplantation of stem cells into the cervical region. The trial then advanced to the final cervical cohort of three patients. The FDA approved the return of three patients from earlier cohorts to receive cervical transplants, making them the first to receive stem cell transplantation in both the lower and upper parts of their spinal cord. The first of these was treated in June 2012, and received five stem cell injections into the cervical region of the back, for a total of 15 injections, including the ten lower-back injections previously received. The last patient in the Phase I trial was treated in August 2012. The trial was designed as a safety trial to treat 18 patients, and conclude six months after the final surgery.
In Mexico City, Neuralstem is expected to commence an ALS Phase I / II trial in the second half of 2013.
- See more at: http://www.neuralstem.com/cell-t ... thash.69tEIJzg.dpuf 作者: Booker 时间: 2013-8-29 10:32
安慰
生活如斯
坚强一些作者: bmatt 时间: 2013-8-29 10:38